Charles River Laboratories International (NYSE:CRL) Shares Acquired Rep. Julie Johnson

Representative Julie Johnson (D-Texas) recently bought shares of Charles River Laboratories International, Inc. (NYSE:CRL). In a filing disclosed on February 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Charles River Laboratories International stock on January 15th. The trade occurred in the Representative’s “MERRILL LYNCH TAX EFFICIENT CORE” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Dell Technologies (NYSE:DELL) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of ALLETE (NYSE:ALE) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of PPG Industries (NYSE:PPG) on 1/27/2025.
• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 1/24/2025.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 1/24/2025.
• Sold $1,001 – $15,000 in shares of Chubb (NYSE:CB) on 1/24/2025.
• Sold $1,001 – $15,000 in shares of Morgan Stanley (NYSE:MS) on 1/24/2025.
• Purchased $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 1/17/2025.

Charles River Laboratories International Trading Down 0.5 %

NYSE:CRL opened at $153.20 on Friday. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $275.00. The firm has a 50-day moving average price of $177.23 and a two-hundred day moving average price of $191.71. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The firm has a market cap of $7.83 billion, a price-to-earnings ratio of 19.17, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37.

Analyst Ratings Changes

CRL has been the topic of several research analyst reports. UBS Group reissued a “neutral” rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a report on Monday, November 18th. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Finally, The Goldman Sachs Group reduced their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Three analysts have rated the stock with a sell rating, fourteen have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $200.79.

Institutional Trading of Charles River Laboratories International

A number of institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in shares of Charles River Laboratories International during the third quarter valued at about $601,000. JPMorgan Chase & Co. increased its holdings in Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after acquiring an additional 85,759 shares during the period. State Street Corp lifted its stake in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after purchasing an additional 41,421 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Charles River Laboratories International by 7.6% in the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after purchasing an additional 3,268 shares during the period. Finally, Neo Ivy Capital Management purchased a new position in shares of Charles River Laboratories International during the 3rd quarter valued at $966,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).